news
Immunotherapy now standard for gut cancer surgery
New Lancet commentary confirms perioperative immunotherapy, specifically anti-PD-1/PD-L1 immune checkpoint inhibitors, are becoming standard for operable gastro-oesophageal cancer globally. This approach, combined with chemotherapy, showed improved survival by leveraging the body's own immune response to target tumors. It's a significant shift in how we approach one of the deadliest cancers.
New Lancet commentary confirms perioperative immunotherapy, specifically anti-PD-1/PD-L1 immune checkpoint inhibitors, are becoming standard for operable gastro-oesophageal cancer globally. This approach, combined with chemotherapy, showed improved survival by leveraging the body's own immune response to target tumors. It's a significant shift in how we approach one of the deadliest cancers.
The architecture take
So, perioperative immunotherapy for gut cancers is now a global standard. That means surgeons are adding these immune checkpoint inhibitors, like anti-PD-1, to chemotherapy before and after removing stomach or oesophageal tumors. This isn't just about shrinking a tumor. It's about training the body's immune cells to actually see and attack cancer, effectively making immunity part of the surgical cleanup crew.
This matters because it pushes the body's immune system to recognize cancer cells that might otherwise stick around after surgery. For readers, it's a reminder that 'health' is more than avoiding illness; it's also how your system handles the inevitable breakdowns. I think we'll see more pre- and post-op protocols across all cancer types leaning into immune modulation. It’s a bigger shift than just a new drug; it's a new strategy for the body at its most vulnerable.